Selumetinib + Dexamethasone
Phase 1/2Terminated 0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Lymphoblastic Leukemia
Conditions
Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult, Acute Lymphoblastic Leukemia, Pediatric, Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Recurrent
Trial Timeline
May 18, 2018 → May 3, 2023
NCT ID
NCT03705507About Selumetinib + Dexamethasone
Selumetinib + Dexamethasone is a phase 1/2 stage product being developed by AstraZeneca for Acute Lymphoblastic Leukemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT03705507. Target conditions include Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult, Acute Lymphoblastic Leukemia, Pediatric.
What happened to similar drugs?
20 of 20 similar drugs in Acute Lymphoblastic Leukemia were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
9
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03705507 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Acute Lymphoblastic Leukemia